December 17, 2017

728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads

Five Innovative Biotech Stocks for the New Year

THIS POST WAS ORIGINALLY PUBLISHED ON THIS SITE Click Here To Read Entire Article

LAS VEGAS, December 7, 2017 /PRNewswire/ —

Microcapspeculators.com News Commentary 

It’s frightening to know that almost 50% of all deaths in high-income countries are the result of cardiovascular diseases (CVDs). Furthermore, the World Health Organization stated that in 2015, about 31% of the deaths around the world were due to CVDs. These diseases related to the heart and blood are expected to continue rising in the coming years due to the aging population and obesity epidemic presenting an enormous opportunity for companies developing treatments for CVDs.

Here are 5 small healthcare stocks tackling cardiovascular diseases:: Endonovo Therapeutics, Inc. (OTC: ENDV), InspireMD, Inc. (NYSE: NSPR), CHF Solutions Inc. (NASDAQ: CHFS), Dextera Surgical, Inc. (NASDAQ: DXTR), and Avinger, Inc. (NASDAQ: AVGR).

Endonovo Therapeutics, Inc. (OTCQB: ENDV) is a developer of non-invasive medical devices that uses electrical stimulation to treat vascular diseases. Its technology is part of the emerging field of bioelectronic medicine, which uses electrical signals in nerves and tissues to treat disease. ENDV’s technology is a non-invasive medical device that uses electromagnetic fields to deliver electrical stimulation to tissues and organs using Faraday’s law of induction. This electrical stimulation promotes the generation of nitric oxide in tissues, which is a potent vasodilator with anti-inflammatory and pro-angiogeneic/tissue regenerative effects. ENDV is developing its platform technology for the treatment of CVDs like cardiovascular disease, peripheral artery disease, renal disease as well as non-alcoholic fatty liver disease (NASH). The company recently announced strong pre-clinical data showing significant improvements in heart function and reduction in remodeling, such as enlarged heart and scarring following myocardial infarction (heart attack). This company seems to be flying under the radar of most investors at the moment, but big Pharma and tech titans like Google and GlaxoSmithKline have taken notice and are investing big in bioelectronic medicine.

InspireMD, Inc. (NYSE: NSPR) is a medical device company focusing on the commercialization of its MicroNet stent technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The company markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the

About The Author

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: